Regeneron Pharmaceuticals Inc (REGN)
968.00
+12.24
(+1.28%)
USD |
NASDAQ |
May 09, 16:00
968.70
+0.70
(+0.07%)
After-Hours: 20:00
Regeneron Pharmaceuticals Cash from Financing (TTM): -1.420B for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -1.420B |
December 31, 2023 | -1.790B |
September 30, 2023 | -1.592B |
June 30, 2023 | -1.909B |
March 31, 2023 | -1.396B |
December 31, 2022 | -1.009B |
September 30, 2022 | -1.668B |
June 30, 2022 | -557.60M |
March 31, 2022 | -574.70M |
December 31, 2021 | -1.006B |
September 30, 2021 | -404.50M |
June 30, 2021 | -177.90M |
March 31, 2021 | -2.672B |
December 31, 2020 | -1.970B |
September 30, 2020 | -2.011B |
June 30, 2020 | -2.634B |
March 31, 2020 | -36.40M |
December 31, 2019 | -252.10M |
September 30, 2019 | 10.60M |
June 30, 2019 | 25.30M |
March 31, 2019 | 29.40M |
December 31, 2018 | -77.10M |
September 30, 2018 | -204.64M |
June 30, 2018 | -216.53M |
March 31, 2018 | -71.81M |
Date | Value |
---|---|
December 31, 2017 | -24.40M |
September 30, 2017 | -305.65M |
June 30, 2017 | -268.78M |
March 31, 2017 | -433.50M |
December 31, 2016 | -700.50M |
September 30, 2016 | -212.72M |
June 30, 2016 | -587.04M |
March 31, 2016 | -559.38M |
December 31, 2015 | -262.80M |
September 30, 2015 | -511.44M |
June 30, 2015 | -160.63M |
March 31, 2015 | -237.10M |
December 31, 2014 | -218.55M |
September 30, 2014 | 134.72M |
June 30, 2014 | 133.09M |
March 31, 2014 | 169.62M |
December 31, 2013 | 72.19M |
September 30, 2013 | -101.44M |
June 30, 2013 | -106.78M |
March 31, 2013 | -68.37M |
December 31, 2012 | -97.65M |
September 30, 2012 | 336.80M |
June 30, 2012 | 338.33M |
March 31, 2012 | 353.46M |
December 31, 2011 | 384.25M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-2.672B
Minimum
Mar 2021
25.30M
Maximum
Jun 2019
-1.152B
Average
-1.203B
Median
Cash from Financing (TTM) Benchmarks
Vertex Pharmaceuticals Inc | -625.00M |
Amgen Inc | -2.169B |
Eli Lilly and Co | 2.772B |
Moderna Inc | -821.00M |
Gilead Sciences Inc | -5.08B |